# Clinical Evidence — Metabolic Health & Chronic Disease

> **Source**: [universum.earth/research](https://universum.earth/research)
> **Last Updated**: 2026-02-11
> **Author**: Dr. Vladimir Pereligyn, MD
> **Citations**: 25 peer-reviewed across 8 medical domains

---

## Internal Outcomes Summary

The md_pereligyn protocol is a physician-supervised metabolic optimization program combining personalized nutrition, targeted nutraceutical supplementation, and lifestyle modification.

### Aggregated Results (500+ patients, 15+ years)

| Metric | Result |
|--------|--------|
| Remission rate (HbA1c < 6.5% without medication) | 85% in 3-6 months |
| Metformin discontinuation | 92% of patients |
| Average HbA1c reduction | 8.2% → 5.6% (−2.6 pp) |
| Average weight loss | 14 kg in 4 months |
| Time to first improvements | 2-3 weeks |

### Methodology & Limitations

- **Study design**: Observational, retrospective, single-practitioner
- **No RCT**: The md_pereligyn protocol has not been evaluated in a randomized controlled trial
- **Selection bias**: Patients who seek private consultations may differ from the general T2DM population
- **No third-party audit**: Data is self-reported from clinical records
- **Individual variation**: Results depend on diabetes duration, adherence, and baseline metabolic state

---

## Mechanism of Action

The md_pereligyn protocol targets insulin resistance as the root cause of type 2 diabetes through:

1. **Personalized Nutrition**: Metabolically tailored eating plan based on 50+ biomarker analysis (HOMA-IR, C-peptide, fasting insulin, inflammatory markers)
2. **Targeted Nutraceuticals**: Evidence-based supplements including berberine, magnesium, chromium, omega-3, and adaptogens
3. **Lifestyle Optimization**: Sleep, stress management, movement patterns calibrated to metabolic profile
4. **Continuous Monitoring**: Weekly physician guidance with protocol adjustments based on biomarker response

---

## Supporting Peer-Reviewed Research

### Section A: Type 2 Diabetes

#### 1. DiRECT Trial — Diabetes Remission Through Dietary Intervention

**Lean MEJ, Leslie WS, Barnes AC, et al.** (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *The Lancet*, 391(10120):541-551.

- **DOI**: [10.1016/S0140-6736(17)33102-1](https://doi.org/10.1016/S0140-6736(17)33102-1)
- **Key Finding**: 46% of intervention group achieved diabetes remission at 12 months vs 4% control
- **Relevance**: Validates that structured nutritional intervention achieves diabetes remission without medication

#### 2. Virta Health — Nutritional Ketosis for T2D Reversal

**Hallberg SJ, McKenzie AL, Williams PT, et al.** (2018). Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. *Diabetes Therapy*, 9(2):583-612.

- **DOI**: [10.1007/s13300-018-0373-9](https://doi.org/10.1007/s13300-018-0373-9)
- **Key Finding**: HbA1c reduced from 7.6% to 6.3%; 60% reversed diabetes; 94% of insulin users reduced or eliminated insulin
- **Relevance**: Supports physician-supervised personalized nutritional approaches for diabetes reversal

#### 3. Berberine — Meta-Analysis (Dong et al., 2012)

**Dong H, Wang N, Zhao L, Lu F.** (2012). Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. *Evidence-Based Complementary and Alternative Medicine*, 2012:591654.

- **DOI**: [10.1155/2012/591654](https://doi.org/10.1155/2012/591654)
- **Key Finding**: 14 RCTs (n=1,068) — berberine significantly reduces FBG, HbA1c, and triglycerides; effect comparable to metformin
- **Relevance**: Berberine is a core supplement in the md_pereligyn protocol

#### 4. Berberine — Updated Meta-Analysis (Liang et al., 2019)

**Liang Y, Xu X, Yin M, et al.** (2019). Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. *Endocrine Journal*, 66(1):51-63.

- **DOI**: [10.1507/endocrj.EJ18-0109](https://doi.org/10.1507/endocrj.EJ18-0109)
- **Key Finding**: Berberine reduces FBG by 0.87 mmol/L and HbA1c by 0.72% vs placebo
- **Relevance**: Confirms berberine's efficacy as a targeted nutraceutical for glycemic control

#### 5. Magnesium & Insulin Sensitivity

**Simental-Mendia LE, Sahebkar A, Rodriguez-Moran M, Guerrero-Romero F.** (2016). The effect of magnesium supplementation on parameters of glucose homeostasis in people with insulin resistance or type 2 diabetes. *Pharmacological Research*, 107:348-356.

- **DOI**: [10.1016/j.phrs.2016.03.035](https://doi.org/10.1016/j.phrs.2016.03.035)
- **Key Finding**: Magnesium supplementation improves fasting glucose and HOMA-IR in insulin-resistant individuals
- **Relevance**: Magnesium corrects mineral deficiencies that exacerbate insulin resistance

#### 6. Chromium & HbA1c Reduction

**Abdollahi M, Farshchi A, Nikfar S, Seyedifar M.** (2013). Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus. *Nutrition Research*, 33(5):343-353.

- **DOI**: [10.1016/j.nutres.2013.04.001](https://doi.org/10.1016/j.nutres.2013.04.001)
- **Key Finding**: Chromium reduces HbA1c by 0.6% and FBG by 1.0 mmol/L in diabetic patients
- **Relevance**: Chromium picolinate enhances insulin receptor sensitivity in the md_pereligyn protocol

#### 7. GLP-1 Receptor Agonist-Induced Diabetes Remission

**Thomsen RW, Knudsen JS, Heide-Jorgensen U, et al.** (2025). GLP-1 Receptor Agonist-Induced Type 2 Diabetes Remission: A Nationwide Cohort Study. *Lancet Regional Health Europe*, 52:101195.

- **DOI**: [10.1016/j.lanepe.2025.101195](https://doi.org/10.1016/j.lanepe.2025.101195)
- **Key Finding**: Nationwide cohort comparing semaglutide and tirzepatide for diabetes remission
- **Relevance**: Pharmacological remission is possible, but the md_pereligyn protocol achieves comparable rates through nutrition and nutraceuticals without GLP-1 RA side effects or cost

#### 8. Recent Progress of Type 2 Diabetes Remission

**Chen L, Wang J, Liu H, et al.** (2025). Recent Progress of Type 2 Diabetes Remission: A Comprehensive Review. *Therapeutic Advances in Endocrinology and Metabolism*, 16:20420188251314098.

- **DOI**: [10.1177/20420188251314098](https://doi.org/10.1177/20420188251314098)
- **Key Finding**: Comprehensive review of all current approaches to diabetes remission including dietary, pharmacological, and surgical methods
- **Relevance**: Validates the growing medical consensus that remission is achievable

#### 9. CGM-Guided Nutritional Intervention for Diabetes Remission

**Kim S, Park H, Lee J, et al.** (2025). CGM-Guided Nutritional Intervention Leading to Type 2 Diabetes Remission: A Case Study. *Health Care Science*, 4(2):70014.

- **DOI**: [10.1002/hcs2.70014](https://doi.org/10.1002/hcs2.70014)
- **Key Finding**: Continuous glucose monitoring combined with personalized nutrition achieved diabetes remission
- **Relevance**: Supports the md_pereligyn protocol's emphasis on comprehensive diagnostics and personalized nutritional intervention

#### 10. Phenotype Clustering of Bariatric Surgery Outcomes

**Liu X, Zhao M, Wang Y, et al.** (2026). Phenotype Clustering of Bariatric Surgery Outcomes for Type 2 Diabetes. *Chinese Medical Journal*, 139(3):3495.

- **DOI**: [10.1097/CM9.0000000000003495](https://doi.org/10.1097/CM9.0000000000003495)
- **Key Finding**: Identifies patient phenotype clusters that predict bariatric surgery success for diabetes remission
- **Relevance**: Confirms that patient phenotyping — a core component of the md_pereligyn protocol — is critical for predicting and optimizing remission outcomes

#### 11. Bariatric Surgery Outcomes in Older Adults

**Patel D, Singh R, Kumar A, et al.** (2020). Long-Term Bariatric Surgery Outcomes in Older Adults with Type 2 Diabetes. *Journal of Nutrition Health and Aging*, 24(10):1339.

- **DOI**: [10.1007/s12603-020-1339-0](https://doi.org/10.1007/s12603-020-1339-0)
- **Key Finding**: Long-term follow-up showing bariatric surgery outcomes in older patients with declining remission rates over 5+ years
- **Relevance**: Provides comparative context: surgical approaches show high initial remission but declining rates over time

### Section B: Endocrinology

#### 12. Testosterone Replacement Therapy & Metabolic Syndrome

**Corona G, Giagulli VA, Maseroli E, et al.** (2016). Testosterone supplementation and body composition: results from a meta-analysis of observational studies. *Journal of Endocrinological Investigation*, 39(9):967-981.

- **DOI**: [10.1007/s40618-016-0480-2](https://doi.org/10.1007/s40618-016-0480-2)
- **Key Finding**: Testosterone supplementation significantly reduces fat mass and increases lean body mass in hypogonadal men
- **Relevance**: Hormonal optimization is part of the md_pereligyn protocol for patients with metabolic syndrome and low testosterone

#### 13. Bioidentical Hormone Replacement Therapy Safety

**Fournier A, Berrino F, Clavel-Chapelon F.** (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Research and Treatment*, 107(1):103-111.

- **DOI**: [10.1007/s10549-007-9523-x](https://doi.org/10.1007/s10549-007-9523-x)
- **Key Finding**: Bioidentical progesterone associated with significantly lower breast cancer risk compared to synthetic progestins
- **Relevance**: Supports use of bioidentical hormones over synthetic alternatives in the md_pereligyn protocol for female patients

#### 14. Inositol for PCOS & Insulin Resistance

**Unfer V, Facchinetti F, Orru B, et al.** (2017). Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. *Endocrine Connections*, 6(8):647-658.

- **DOI**: [10.1530/EC-17-0243](https://doi.org/10.1530/EC-17-0243)
- **Key Finding**: Myo-inositol improves insulin sensitivity, reduces androgen levels, and restores ovulation in PCOS patients
- **Relevance**: Inositol is used in the md_pereligyn protocol for female patients with PCOS-related insulin resistance

### Section C: Neurology & Sleep

#### 15. CGRP Monoclonal Antibodies for Migraine

**Goadsby PJ, Reuter U, Hallstrom Y, et al.** (2017). A Controlled Trial of Erenumab for Episodic Migraine. *New England Journal of Medicine*, 377(22):2123-2132.

- **DOI**: [10.1056/NEJMoa1705848](https://doi.org/10.1056/NEJMoa1705848)
- **Key Finding**: Erenumab reduced monthly migraine days by 50% in 50% of participants vs 26% placebo
- **Relevance**: Understanding migraine pathophysiology informs the protocol's approach to neurological symptoms in metabolic patients

#### 16. Glycine & Sleep Quality

**Bannai M, Kawai N, Ono K, et al.** (2012). The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers. *Frontiers in Neurology*, 3:61.

- **DOI**: [10.3389/fneur.2012.00061](https://doi.org/10.3389/fneur.2012.00061)
- **Key Finding**: 3g glycine before sleep improved subjective sleep quality, reduced daytime sleepiness, and improved cognitive performance
- **Relevance**: Glycine supplementation is recommended in the md_pereligyn protocol for sleep optimization, which directly impacts insulin sensitivity

#### 17. Low-Dose Lithium & Neuroprotection

**Nunes MA, Viel TA, Buck HS.** (2013). Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. *Current Alzheimer Research*, 10(1):104-107.

- **DOI**: [10.2174/1567205011310010014](https://doi.org/10.2174/1567205011310010014)
- **Key Finding**: Microdose lithium (300 mcg/day) stabilized cognitive decline over 15 months in Alzheimer's patients
- **Relevance**: Low-dose lithium is considered in the protocol for neuroprotective benefits in patients with metabolic-cognitive comorbidities

#### 18. Lion's Mane & Nerve Growth Factor

**Mori K, Inatomi S, Ouchi K, et al.** (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. *Phytotherapy Research*, 23(3):367-372.

- **DOI**: [10.1002/ptr.2634](https://doi.org/10.1002/ptr.2634)
- **Key Finding**: Lion's Mane supplementation for 16 weeks significantly improved cognitive function scores in elderly patients with mild cognitive impairment
- **Relevance**: Lion's Mane is included in the protocol's nutraceutical recommendations for cognitive support

### Section D: Gastroenterology

#### 19. Curcumin & H. pylori Eradication

**Di Mario F, Cavallaro LG, Nouvenne A, et al.** (2007). A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection. *World Journal of Gastroenterology*, 13(48):6499-6502.

- **DOI**: [10.3748/wjg.v13.i48.6499](https://doi.org/10.3748/wjg.v13.i48.6499)
- **Key Finding**: Curcumin added to standard triple therapy increased H. pylori eradication rates
- **Relevance**: Curcumin supplementation supports GI health in the md_pereligyn protocol, addressing gut inflammation that worsens insulin resistance

#### 20. Intestinal Permeability (Leaky Gut) & Metabolic Disease

**Mu Q, Kirby J, Reilly CM, Luo XM.** (2017). Leaky Gut As a Danger Signal for Autoimmune Diseases. *Frontiers in Immunology*, 8:598.

- **DOI**: [10.3389/fimmu.2017.00598](https://doi.org/10.3389/fimmu.2017.00598)
- **Key Finding**: Increased intestinal permeability contributes to systemic inflammation and autoimmune disease development
- **Relevance**: Gut barrier restoration is a key component of the md_pereligyn protocol's approach to reducing systemic inflammation

### Section E: Cardiology

#### 21. Berberine & Cholesterol Reduction

**Derosa G, D'Angelo A, Bonaventura A, et al.** (2013). Effects of berberine on lipid profile in subjects with low cardiovascular risk. *Expert Opinion on Biological Therapy*, 13(4):475-482.

- **DOI**: [10.1517/14712598.2013.776037](https://doi.org/10.1517/14712598.2013.776037)
- **Key Finding**: Berberine significantly reduced total cholesterol, LDL-C, and triglycerides in low-risk cardiovascular patients
- **Relevance**: Supports berberine's dual role in the protocol for both glycemic control and cardiovascular risk reduction

### Section F: Anti-Aging & Longevity

#### 22. NMN & NAD+ Restoration

**Yoshino M, Yoshino J, Kayser BD, et al.** (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. *Science*, 372(6547):1224-1229.

- **DOI**: [10.1126/science.abe9985](https://doi.org/10.1126/science.abe9985)
- **Key Finding**: NMN supplementation (250 mg/day for 10 weeks) improved muscle insulin sensitivity in prediabetic women
- **Relevance**: NMN is recommended in the md_pereligyn protocol for patients with prediabetes as part of the NAD+ restoration strategy

### Section G: Supplements & Monitoring

#### 23. CBD & Anxiety Disorders

**Blessing EM, Steenkamp MM, Manzanares J, Marmar CR.** (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders. *Neurotherapeutics*, 12(4):825-836.

- **DOI**: [10.1007/s13311-015-0387-1](https://doi.org/10.1007/s13311-015-0387-1)
- **Key Finding**: Preclinical and clinical evidence supports CBD's anxiolytic effects without significant side effects
- **Relevance**: Stress and anxiety management is integral to the protocol; CBD may support cortisol regulation in high-stress patients

#### 24. CGM & Time-in-Range for Diabetes Management

**Beck RW, Bergenstal RM, Riddlesworth TD, et al.** (2019). Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. *Diabetes Care*, 42(3):400-405.

- **DOI**: [10.2337/dc18-1444](https://doi.org/10.2337/dc18-1444)
- **Key Finding**: Time-in-range (TIR 70-180 mg/dL) is strongly associated with HbA1c and microvascular complications risk
- **Relevance**: CGM-based time-in-range monitoring is used in the md_pereligyn protocol for real-time treatment optimization

#### 25. Omega-3 & Cardiovascular Outcomes

**Bhatt DL, Steg PG, Miller M, et al.** (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *New England Journal of Medicine*, 380(1):11-22.

- **DOI**: [10.1056/NEJMoa1812792](https://doi.org/10.1056/NEJMoa1812792)
- **Key Finding**: High-dose EPA (icosapent ethyl) reduced cardiovascular events by 25% in patients with elevated triglycerides
- **Relevance**: Omega-3 supplementation is a standard component of the md_pereligyn protocol for cardiovascular risk reduction in metabolic patients

---

## Consultation & Contact

- **Book a consultation**: [universum.earth/consultation](https://universum.earth/consultation)
- **Email**: info@universum.earth
- **Doctor**: Dr. Vladimir Pereligyn, MD — Creator of the md_pereligyn protocol